Valuation Alkermes plc

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2026 BST			5-day change	1st Jan Change
37.48 ^USD	-2.29%		+7.12%	+33.95%

05-12	Alkermes Plc Announces Positive Topline Results From REVITALYZ? Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia	CI
05-12	Alkermes Phase 3 Trial Meets Primary Endpoint for Hypersomnia Treatment	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Capitalization ¹	3,761	4,293	4,629	4,653	4,620	6,247	-	-
Change	-	14.15%	7.82%	0.52%	-0.72%	35.22%	-	-
Enterprise Value (EV) ¹	3,291	3,847	4,107	4,362	4,032	7,208	6,949	6,719
Change	-	16.87%	6.76%	6.23%	-7.58%	78.79%	-3.6%	-3.3%
P/E ratio	-77.5x	-26.9x	13.2x	13.3x	19.6x	-95.1x	66.3x	27.6x
PBR	3.36x	4.11x	3.85x	3.18x	2.55x	3.39x	2.99x	2.55x
PEG	-	-0x	-0x	3.99x	-0.6x	1x	-0x	0x
Capitalization / Revenue	3.2x	3.86x	2.78x	2.99x	3.13x	3.45x	3.31x	3.01x
EV / Revenue	2.8x	3.46x	2.47x	2.8x	2.73x	3.98x	3.68x	3.24x
EV / EBITDA	66.7x	-59.7x	8.44x	9.64x	14.1x	21.1x	18x	12.7x
EV / EBIT	-112x	-27x	9.92x	10.4x	15.9x	127x	30.8x	18.2x
EV / FCF	44.7x	-224x	11.6x	10.8x	8.39x	20.5x	14.7x	9.68x
FCF Yield	2.24%	-0.45%	8.6%	9.3%	11.9%	4.88%	6.82%	10.3%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-0.3	-0.97	2.1	2.17	1.43	-0.3943	0.5653	1.358
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	1,174	1,112	1,663	1,558	1,476	1,811	1,888	2,075
EBITDA ¹	49.37	-64.4	486.7	452.4	285.6	341.6	386.2	530.9
EBIT ¹	-29.29	-142.3	414.1	420.6	254	56.93	225.9	368.9
Net income ¹	-48.17	-158.3	355.8	367.1	241.7	-65.12	106.4	233.7
Net Debt ¹	-469.9	-446.8	-522.6	-291.1	-588.4	961.2	701.5	472.2
Reference price ²	23.26	26.13	27.74	28.76	27.98	37.48	37.48	37.48
Nbr of stocks (in thousands)	161,705	164,312	166,881	161,803	165,118	166,676	-	-
Announcement Date	16/02/22	16/02/23	15/02/24	12/02/25	25/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ALKERMES PLC	-95.05x	3.98x	21.1x	-.--%	6.25B
LONZA GROUP AG	28.4x	5.05x	15.65x	1.16%	41.67B
BEONE MEDICINES AG	44.43x	4.44x	28.32x	-.--%	32.6B
REVOLUTION MEDICINES, INC.	-18.41x	283.77x	-16.54x	-.--%	30.97B
IQVIA HOLDINGS INC.	20.59x	2.44x	10.54x	-.--%	28.23B
CELLTRION, INC.	30.22x	7.79x	20x	0.41%	26.41B
IONIS PHARMACEUTICALS, INC.	-20.9x	13.53x	-20.96x	-.--%	12.27B
EUROFINS SCIENTIFIC SE	20.54x	1.83x	8.04x	1.3%	12.12B
Average	1.23x	40.35x	8.27x	0.36%	23.81B
Weighted average by Cap.	14.91x	50.55x	9.77x	0.39%